The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Donald W. Glazer net worth and biography

Donald Glazer Biography and Net Worth

Director of BeiGene

Donald W. Glazer has served as a member of our Board of Directors since February 2013. Mr. Glazer has served as a member of the Board of Trustees of GMO Trust, a mutual fund group, since 2000 and as the Chairman of the Board of GMO Trust since 2005. Mr. Glazer was a Co-Founder and Secretary, and from 2002 until 2010, Vice Chairman, of Provant, Inc., a provider of performance improvement training solutions. From 1992 to 1995 Mr. Glazer was President of Mugar/Glazer Holdings and from 1992 to 1993 served as Vice Chairman—Finance of New England Television Corp and WHDH-TV, Inc. From 1997 to the present, Mr. Glazer has served as Advisory Counsel to Goodwin Procter LLP. From 1970 to 1978 Mr. Glazer was an associate and from 1978 to 1992 a partner at Ropes & Gray LLP, a Boston law firm. At Ropes & Gray, Mr. Glazer chaired the firm’s Emerging Companies Group. Mr. Glazer was also a Lecturer in Law at Harvard Law School from 1978 to 1991, teaching a course called The Business Lawyer. Mr. Glazer is a former member of the boards of directors of Environics Inc.; Kronos Incorporated; Reflective Technologies, Inc.; and Teleco Oilfield Services Inc. Mr. Glazer received his A.B. from Dartmouth College; J.D. from Harvard Law School, where he was an editor of the Harvard Law Review; and L.L.M. from the University of Pennsylvania Law School. Additionally, Mr. Glazer is a co-author of both Glazer and FitzGibbon on Legal Opinions, Third Edition (Aspen Publishers) and Massachusetts Corporation Law & Practice, Second Edition (Aspen Publishers).

What is Donald W. Glazer's net worth?: The estimated net worth of Donald W. Glazer is at least $486.14 million as of May 19th, 2020. Mr. Glazer owns 3,497,678 shares of BeiGene stock worth more than $486,142,265 as of April 24th. This net worth approximation does not reflect any other assets that Mr. Glazer may own. Learn More about Donald W. Glazer's net worth.
How do I contact Donald W. Glazer?: The corporate mailing address for Mr. Glazer and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Donald W. Glazer's contact information.
Has Donald W. Glazer been buying or selling shares of BeiGene?: Donald W. Glazer has not been actively trading shares of BeiGene in the last ninety days. Most recently, Donald W. Glazer sold 10,000 shares of the business's stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $169.84, for a transaction totalling $1,698,400.00. Following the completion of the sale, the director now directly owns 3,497,678 shares of the company's stock, valued at $594,045,631.52. Learn More on Donald W. Glazer's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 16 times. They sold a total of 2,769,908 shares worth more than $568,875,239.08. The most recent insider tranaction occured on April, 10th when CEO John Oyler sold 26,716 shares worth more than $3,977,745.24. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 4/10/2024.

Donald W. Glazer Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/19/2020	Sell	10,000	$169.84	$1,698,400.00	3,497,678
5/13/2019	Sell	15,027	$125.11	$1,880,027.97	3,911,518
3/14/2019	Sell	14,973	$136.10	$2,037,825.30	4,106,869
8/30/2018	Sell	2,000	$179.00	$358,000.00	14,384
7/10/2017	Sell	10,810	$72.15	$779,941.50	7,206
9/28/2016	Sell	41,463	$30.66	$1,271,255.58	4,881,997
9/27/2016	Sell	47,149	$29.61	$1,396,081.89	4,881,997
9/23/2016	Sell	36,443	$31.02	$1,130,461.86	4,881,997
9/21/2016	Sell	67,252	$31.42	$2,113,057.84	4,882,000

Donald W. Glazer Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $138.99

$134.68

$142.22

50 Day Range

MA: $154.71

$129.52

$179.69

2 Week Range

Now: $138.99

$126.97

$266.67

Volume

203,615 shs

Average Volume

257,968 shs

Market Capitalization

$13.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

See how you can invest alongside him